| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 11/20/2003 | US20030216404 Hydroxamic acid derivatives |
| 11/20/2003 | US20030216403 An aromatic alkylamino compound containing a lipophilic group useful as antithrombotic agent as well as treats asthma |
| 11/20/2003 | US20030216401 Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles |
| 11/20/2003 | US20030216400 Administering folic acid or a folate and tetrahydrobiopterin (BH4) for reducing superoxide (O2) production and enhancing nitric oxide (NO) synthesis |
| 11/20/2003 | US20030216399 A dipeptide containing bi or tri-heterocylic ring with nitrogen atom which forms amide with carbonyl group of dipeptide chain; useful for treating osteoporosis, congestive heart failure and accelerates wound healing |
| 11/20/2003 | US20030216398 Soluble beta amyloid precursor protein secretion promoters |
| 11/20/2003 | US20030216397 A compound having a fused ecteinascidin five ring system with a 1,4 bridge; anticarcinogenic agent |
| 11/20/2003 | US20030216395 Imidazo-triazine derivatives as ligands for GABA receptors |
| 11/20/2003 | US20030216393 Administering to a patient in need an effective pain treating amount of a substituted 1-aminobutan-3-ol compound to treat migraines, hyperalgesia, inflammatory pain, and post-operative pain |
| 11/20/2003 | US20030216392 Aryl or heteroaryl substituted ethylcarbonylsulfonamide derivatives used as inhibitors of neutrophils chemotaxis and degranulation induced by interleukin 8 |
| 11/20/2003 | US20030216391 Oxazole or thiazole-ethyl-oxy-indane acetic acid derivatives; useful for the treatment of diseases such as diabetes, obesity, hyperlipidemia and atherosclerosis |
| 11/20/2003 | US20030216390 Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues |
| 11/20/2003 | US20030216389 Therapeutic morpholino-substituted compounds |
| 11/20/2003 | US20030216388 Cyclocarbamate derivatives as progesterone receptor modulators |
| 11/20/2003 | US20030216387 Benzamide derivatives, particularly esterified cisapride derivatives |
| 11/20/2003 | US20030216385 Triazole derivatives |
| 11/20/2003 | US20030216384 Composition and method for treating hypertension |
| 11/20/2003 | US20030216383 Compounds useful as reversible inhibitors of cysteine proteases |
| 11/20/2003 | US20030216382 Useful for the treatment and/or prophylaxis of diseases associated with dipeptidyl peptidase, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance |
| 11/20/2003 | US20030216380 Novel gamma secretase inhibitors |
| 11/20/2003 | US20030216379 Substituted fused pyrazolecarboxylic acid arylamides and related compounds |
| 11/20/2003 | US20030216378 Azepino[4,5-b]pyrano[3,2-e]indoles |
| 11/20/2003 | US20030216377 Vitronectin receptor antagonist |
| 11/20/2003 | US20030216375 Sulfonamide substituted diphenyl thiourea compounds; use thereof in treating IL-8, GRO alpha, GRO beta, GRO gamma, NAP-2, and ENA-78 mediated diseases |
| 11/20/2003 | US20030216374 Antibiotic oxazolidinone derivatives |
| 11/20/2003 | US20030216373 Activity against both Gram-positive and Gram-negative pathogens are generally regarded as having a broad spectrum of activity |
| 11/20/2003 | US20030216372 Inhibitors of serine and metallo-beta-lactamases |
| 11/20/2003 | US20030216371 Synthetic catalytic free radical scavengers usefuyl as antioxidants for prevention and therapy of disease |
| 11/20/2003 | US20030216369 Administering compounds which inhibit heat shock protein 90 proteins; methods block Rb negative or deficient cells in the G2/M phase of the cell cycle and rapidly causes their destruction |
| 11/20/2003 | US20030216368 Hormone replacement therapy |
| 11/20/2003 | US20030216367 In perimenopausal, menopausal, and postmenopausal women through the sequential administration of combinations of conjugated estrogens and trimegestone |
| 11/20/2003 | US20030216366 Step-down estrogen therapy |
| 11/20/2003 | US20030216365 Use of mometasone furoate for treating airway passage and lung diseases |
| 11/20/2003 | US20030216364 Dermatological Formulation |
| 11/20/2003 | US20030216361 Therapeutic compositions effective against gram positive bacteria |
| 11/20/2003 | US20030216360 Subjecting a supersaturated solution containing a steroid to wet milling while crystallizing, in order to obtain a primary particle suspension. |
| 11/20/2003 | US20030216359 Administering vitamin D or a derivative and a cytotoxic agent or a glucocorticoid and, optionally, a bisphosphonate |
| 11/20/2003 | US20030216358 Method for enhancing bone mineral density gain |
| 11/20/2003 | US20030216357 Compositions for improving lipid content in the blood |
| 11/20/2003 | US20030216356 Cause the selective destruction of tumour vasculature; are used to inhibit and/or reverse, and/or alleviate symptoms of angiogenesis |
| 11/20/2003 | US20030216355 Process for preventing protozoal diseases |
| 11/20/2003 | US20030216354 Prepared from Penicillium sp.; treatment of plasmodia, trypanosomes and carcinosis. |
| 11/20/2003 | US20030216353 Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| 11/20/2003 | US20030216352 Multicomponent complex for use with a substrate |
| 11/20/2003 | US20030216350 Administering orally a single formulation having 0.3-10 mg vitamin B12 and 0.1-0.4 mg folic acid. |
| 11/20/2003 | US20030216349 Method for treating arrhythmias |
| 11/20/2003 | US20030216348 Aminosugar, glycosaminoglycan, and S-Adenosylmethionine composition for the treatment and repair of connective tissue |
| 11/20/2003 | US20030216347 Genetic material composed of a polynucleotide complexed with an amphipathic compound, a polymer or a nonviral vector is delivered to the parenchymal cell altering its endogenous properties |
| 11/20/2003 | US20030216344 Antisense oligonucleotide against human acetylcholinesterase (AChE) and uses thereof |
| 11/20/2003 | US20030216343 Expression vectors for stimulating an immune response and methods of using the same |
| 11/20/2003 | US20030216342 Expression vectors for stimulating an immune response and methods of using the same |
| 11/20/2003 | US20030216340 Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences |
| 11/20/2003 | US20030216335 Treating endometriosis by contacting the subject with a nucleic acid that modulates the expression of VEGF, VEGFR1, and/or VEGFR2 |
| 11/20/2003 | US20030216333 Antisense modulation of glycogen synthase kinase3 alpha expression |
| 11/20/2003 | US20030216331 Micelles |
| 11/20/2003 | US20030216330 Especially for methicillin or vancomycin resistant Staphylococcus aureus, vancomycin resistant Enterococci or glycopeptide-intermediate Staphylococcus aureus |
| 11/20/2003 | US20030216329 Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s) |
| 11/20/2003 | US20030216328 Androgen derivatives and uses thereof |
| 11/20/2003 | US20030216326 Compositions comprising lignin and methods of making and using the same |
| 11/20/2003 | US20030216325 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus |
| 11/20/2003 | US20030216324 Five-member heterocyclic compounds substituted with an alpha-amino carbonyl group; antiasthma agents |
| 11/20/2003 | US20030216314 Methods of reducing angiogenesis |
| 11/20/2003 | US20030216305 Identification and characterization of a polypeptide having homology to the sarcoma-amplified protein SAS |
| 11/20/2003 | US20030216303 Emulsion preconcentrates containing cyclosporin or a macrolide |
| 11/20/2003 | US20030216297 Pharmaceutical composition |
| 11/20/2003 | US20030216294 Synergistic effect of a sulfonylurea and/or non-sulfonylurea Kchannel blocker, and a phosphodiesterase 3 type inhibitor |
| 11/20/2003 | US20030216290 Methods and compositions of treating and/or preventing diabetic retinopathy with pericyte apoptosis inhibitors |
| 11/20/2003 | US20030216288 Methods and compositions for treating aids and HIV-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules |
| 11/20/2003 | US20030216287 N-(2-chlorophenyl) hydroxy- or alkoxyalkanamides, e.g.,N-(5-Chloro-2-hydroxyphenyl)-2-(2-hydroxyphenoxy)acetamid e); can deliver a broad range of active agents by various routes. |
| 11/20/2003 | US20030216285 Selected from the group consisting of alloxazines and photosensitizers |
| 11/20/2003 | US20030215943 Antisense modulation of apolipoprotein B expression |
| 11/20/2003 | US20030215918 Comprises nucleotide sequences coding tyrosine kinase receptor binding protein (EFL-1) for treating and diagnosing cell proliferative disorders |
| 11/20/2003 | US20030215889 Membrane preparation comprising calcium channel transport protein for screening and identifying modulator of ion transport; for prevention and treatment of nervous tissue injuries and diabetes |
| 11/20/2003 | US20030215885 Using presence of antibody complex to diagnose inflammatory diseases; antiiflammatory agents; immunoassay |
| 11/20/2003 | US20030215879 Comprise enzymatic polypeptide for use in the treatment of inflammation; aniinflammatory agents |
| 11/20/2003 | US20030215869 Use of azetidinone compounds |
| 11/20/2003 | US20030215861 Methods of treating a BRCA associated disorder |
| 11/20/2003 | US20030215852 Novel pancortin-Pablo protein interactions and methods of use thereof |
| 11/20/2003 | US20030215840 Identifying compounds capable of treating atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, heart failure, thrombosis and endothelial cell disorders |
| 11/20/2003 | US20030215823 Uses of galanin GALR2 receptors |
| 11/20/2003 | US20030215785 Solution containing platelet activation inhibitors for pathogen reducing and storing blood platelets |
| 11/20/2003 | US20030215781 Containing alkali ions, electrolytes, a buffer, polyol, saccharide and hydroxamic acid derivatives |
| 11/20/2003 | US20030215562 Crystal structure, enzyme resistance, nonhydrolyzing, nonabsorption in the small intestine, and passes into the large intestine, fermentation by colonic microflora to maintain colonic health |
| 11/20/2003 | US20030215561 Crystal structure, enzyme resistance, nonhydrolyzing, nonabsorption in the small intestine, and passes into the large intestine, fermentation by colonic microflora to maintain colonic health |
| 11/20/2003 | US20030215556 Reduced calorie fat compositions |
| 11/20/2003 | US20030215534 Mixing psyllium seeds with basic solutions, then seperating the insoluble and soluble gels, disinfecting, and acidifying to form compressible polysaccharides used as dietary fiber |
| 11/20/2003 | US20030215533 Method of preventing respiratory infections |
| 11/20/2003 | US20030215532 Cooling or heating sensitizers such as oleoresin or spilanthol, for use in foods, drugs or cosmetics |
| 11/20/2003 | US20030215528 Prophylaxis and prevention of cancer, tumors, hyperplasia, hypertrophy or dysplasia comprising administering nitrates such as nitroglycerin; angiogenesis inhibitors |
| 11/20/2003 | US20030215527 Novel substituted benzimidazole dosage forms and method of using same |
| 11/20/2003 | US20030215526 Stable formulations of angiotensin converting enzyme (ACE) inhibitors |
| 11/20/2003 | US20030215524 Stable pharmaceutical composition useful for treating gastrointestinal disorders |
| 11/20/2003 | US20030215522 Personal care compositions comprising a zinc containing material in an aqueous surfactant composition |
| 11/20/2003 | US20030215519 Preferential plugging of vascular sytems of mammals using microstructure particles comprising hydrolytically degradable crosslinked gels |
| 11/20/2003 | US20030215518 Immediate release eplerenone compositions |
| 11/20/2003 | US20030215516 Wet milling saturated solutions containing drugs such as steroids, while crystallizing to obtain microstructure particles in suspension |
| 11/20/2003 | US20030215514 Dispersible macromolecule compositions and methods for their preparation and use |
| 11/20/2003 | US20030215512 Stable glassy state powder formulations |
| 11/20/2003 | US20030215510 A delayed delivery drug dose to a fluid environment consists of a dose of drug, a second formulation with imbibes fluid and expands, a wall that confines both and permeable to the passage of fluid, a subcoat of hydroxyalkyl cellulose |
| 11/20/2003 | US20030215509 Coated sustained release tablets of a hygroscopic compound for once-a-day therapy |